Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
(2020) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 12(1).- Abstract
Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)1-42 levels varied by tube type, using a low-bind FBT reduced variation. Aβ1-42 levels were higher with no mixing versus... (More)
Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)1-42 levels varied by tube type, using a low-bind FBT reduced variation. Aβ1-42 levels were higher with no mixing versus roller/inversion mixing. Aβ1-42 levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ1-40 levels were less strongly affected. Phospho-tau and total-tau levels were largely unaffected. Discussion: We propose an easy-to-use, standardized, routine-use pre-analytical protocol, using low-bind FBTs, for measuring AD CSF biomarkers in clinical practice.
(Less)
- author
- Hansson, Oskar LU ; Rutz, Sandra ; Zetterberg, Henrik LU ; Bauer, Ekaterina ; Hähl, Teresa ; Manuilova, Ekaterina ; Mert, Mehmet Can ; Wahl, Simone ; Blennow, Kaj LU and Stomrud, Erik LU
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, amyloid beta, biomarker, cerebrospinal fluid, diagnosis, pre-analytical, tau
- in
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- volume
- 12
- issue
- 1
- article number
- e12137
- publisher
- Elsevier
- external identifiers
-
- scopus:85100542916
- pmid:33354617
- ISSN
- 2352-8729
- DOI
- 10.1002/dad2.12137
- language
- English
- LU publication?
- yes
- id
- 317648db-aa5e-433d-8c0a-938df9a2344d
- date added to LUP
- 2021-02-26 14:28:47
- date last changed
- 2024-10-03 19:34:46
@article{317648db-aa5e-433d-8c0a-938df9a2344d, abstract = {{<p>Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)<sub>1-42</sub> levels varied by tube type, using a low-bind FBT reduced variation. Aβ<sub>1-42</sub> levels were higher with no mixing versus roller/inversion mixing. Aβ<sub>1-42</sub> levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ<sub>1-40</sub> levels were less strongly affected. Phospho-tau and total-tau levels were largely unaffected. Discussion: We propose an easy-to-use, standardized, routine-use pre-analytical protocol, using low-bind FBTs, for measuring AD CSF biomarkers in clinical practice.</p>}}, author = {{Hansson, Oskar and Rutz, Sandra and Zetterberg, Henrik and Bauer, Ekaterina and Hähl, Teresa and Manuilova, Ekaterina and Mert, Mehmet Can and Wahl, Simone and Blennow, Kaj and Stomrud, Erik}}, issn = {{2352-8729}}, keywords = {{Alzheimer's disease; amyloid beta; biomarker; cerebrospinal fluid; diagnosis; pre-analytical; tau}}, language = {{eng}}, number = {{1}}, publisher = {{Elsevier}}, series = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}}, title = {{Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF}}, url = {{http://dx.doi.org/10.1002/dad2.12137}}, doi = {{10.1002/dad2.12137}}, volume = {{12}}, year = {{2020}}, }